###begin article-title 0
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
The Pace of Prostatic Intraepithelial Neoplasia Development Is Determined by the Timing of Pten Tumor Suppressor Gene Excision
###end article-title 0
###begin p 1
Conceived and designed the experiments: HAL FRJ. Performed the experiments: HAL MLV. Analyzed the data: HAL HB. Contributed reagents/materials/analysis tools: AP. Wrote the paper: HAL.
###end p 1
###begin p 2
###xml 265 269 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 453 457 453 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 657 661 657 661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 770 774 770 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1061 1065 1061 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1156 1160 1156 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1610 1614 1598 1602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1926 1930 1914 1918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 60 65 <span type="species:ncbi:9606">human</span>
###xml 277 283 <span type="species:ncbi:10090">murine</span>
###xml 346 352 <span type="species:ncbi:9606">humans</span>
###xml 468 473 <span type="species:ncbi:10090">mouse</span>
###xml 881 885 <span type="species:ncbi:10090">mice</span>
###xml 1040 1044 <span type="species:ncbi:10090">mice</span>
Loss of the PTEN tumor suppressor is a common occurrence in human prostate cancer, particularly in advanced disease. In keeping with its role as a pivotal upstream regulator of the phosphatidylinositol 3-kinase signaling pathway, experimentally-induced deletion of Pten in the murine prostate invariably results in neoplasia. However, and unlike humans where prostate tumorigenesis likely evolves over decades, disease progression in the constitutively Pten deficient mouse prostate is relatively rapid, culminating in invasive cancer within several weeks post-puberty. Given that the prostate undergoes rapid androgen-dependent growth at puberty, and that Pten excisions during this time might be especially tumorigenic, we hypothesized that delaying prostate-specific Pten deletions until immediately after puberty might alter the pace of tumorigenesis. To this end we generated mice with a tamoxifen-inducible Cre recombinase transgene enabling temporal control over prostate-specific gene alterations. This line was then interbred with mice carrying floxed Pten alleles. Despite evidence of increased Akt/mTOR/S6K axis activity at early time points in Pten-deficient epithelial cells, excisions induced in the post-pubertal (6 wk-old) prostate yielded gradual acquisition of a range of lesions. These progressed from pre-malignant changes (nuclear atypia, focal hyperplasia) and low grade prostatic intraepithelial neoplasia (PIN) at 16-20 wks post-tamoxifen exposure, to overtly malignant lesions by approximately1 yr of age, characterized by high-grade PIN and microinvasive carcinoma. In contrast, when Pten excisions were triggered in the pre-pubertal (2 week-old) prostate, neoplasia evolved over a more abbreviated time-frame, with a spectrum of premalignant lesions, as well as overt PIN and microinvasive carcinoma by 10-12 wks post-tamoxifen exposure. These results indicate that the developmental stage at which Pten deletions are induced dictates the pace of PIN development.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 151 154 151 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Tomlins1">[1]</xref>
###xml 156 159 156 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Hughes1">[2]</xref>
###xml 196 200 196 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 454 457 442 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Tomlins2">[3]</xref>
###xml 496 500 484 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 590 593 578 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Wang1">[4]</xref>
###xml 594 597 582 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Majumder1">[8]</xref>
###xml 780 783 768 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Hawkins1">[9]</xref>
###xml 1226 1229 1214 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Hawkins1">[9]</xref>
###xml 1438 1442 1426 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Vanhaesebroeck1">[10]</xref>
###xml 1444 1448 1432 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Chow1">[11]</xref>
###xml 1580 1584 1568 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Faivre1">[12]</xref>
###xml 109 114 <span type="species:ncbi:9606">human</span>
###xml 519 525 <span type="species:ncbi:10090">murine</span>
Genetic alterations in a variety of different oncogenes and tumor suppressor genes have been associated with human prostate tumorigenesis (reviewed in [1]; [2]). Of these, mutations involving the PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor are amongst the most commonly encountered, with loss of function mutations being reported in approximately30% of primary cancers, and in more than 60% of metastases (reviewed in [3]). Echoing these findings, deletion of Pten in the developing murine prostate leads to early onset and rapidly progressive neoplasia [4]-[8]. PTEN's importance lies primarily in its ability to regulate the levels of membrane PI(3,4,5)P3 (PIP3) generated by the actions of phosphatidylinositol 3'-kinase (PI3K) (reviewed in [9]). PTEN dephosphorylates PIP3, yielding PI(4,5)P2, thus PI3K activity (for example, in response to receptor protein tyrosine kinase activation) in Pten-deficient cells results in higher and more sustained levels of PIP3. PIP3-dependent pathways, in turn, regulate various cellular processes, including, rate of protein translation, susceptibility to apoptosis and anoikis, entry into the cell cycle, differentiation, and motility (reviewed in [9]). Key effectors lying downstream of PIP3 that promote tumorigenesis include such molecules as PDK1, Akt/protein kinase B (PKB), and the two mammalian target of rapamycin-containing complexes, mTOR1 and mTOR2 [10], [11]. The PI3K/AKT/mTOR pathway in particular often plays a fundamental role in supporting cancer cell metabolism, growth, and survival [12].
###end p 4
###begin p 5
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Carver1">[13]</xref>
###xml 289 293 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 507 510 507 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Wang1">[4]</xref>
###xml 512 516 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Kasper1">[14]</xref>
###xml 517 521 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Wu1">[17]</xref>
###xml 535 539 535 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Kasper2">[18]</xref>
###xml 940 944 940 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Jemal1">[19]</xref>
###xml 1182 1186 1182 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-AbateShen1">[20]</xref>
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
###xml 117 122 <span type="species:ncbi:9606">human</span>
###xml 327 333 <span type="species:ncbi:10090">murine</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
###xml 684 690 <span type="species:ncbi:9606">humans</span>
###xml 917 920 <span type="species:ncbi:9606">men</span>
###xml 983 988 <span type="species:ncbi:10090">mouse</span>
###xml 1085 1090 <span type="species:ncbi:9606">human</span>
The ability to manipulate the mouse genome has allowed the evaluation of genetic alterations potentially involved in human prostate tumorigenesis, as well as the identification and preclinical validation of molecular targets for potential pharmacological intervention [13]. In the case of PTEN, loss of the cognate gene in the murine prostate has been shown to trigger rapid onset of disease, with prostatic intraepithelial neoplasia (PIN) and invasive adenocarcinomas ensuing within a few weeks of puberty [4], [14]-[17]; reviewed in [18]). Even taking into account the relatively short lifespan of mice, such a rapid evolution of disease is not reflective of disease progression in humans, that likely takes place over decades as a consequence of an accumulation of genetic changes and where intraepithelial lesions tend only to be observed beyond middle age. Indeed, most cases of prostate cancer are diagnosed in men over the age of 65 [19]. Thus far there has been a paucity of mouse models of prostate cancer able to clearly delineate the various pathological grades seen in the human disease, from the earliest premalignant changes to overt invasive carcinoma and metastasis [20].
###end p 5
###begin p 6
###xml 618 622 618 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Luchman1">[21]</xref>
###xml 26 31 <span type="species:ncbi:10090">mouse</span>
###xml 99 104 <span type="species:ncbi:9606">human</span>
###xml 403 408 <span type="species:ncbi:9606">human</span>
###xml 447 453 <span type="species:ncbi:10090">murine</span>
###xml 586 589 <span type="species:ncbi:10116">rat</span>
There has been a need for mouse models that better mimic the slow progression to cancer typical of human prostate tumorigenesis. One of the steps towards attaining this goal has been the development of inducible systems that allow genetic alterations to be confined to the prostatic epithelium of the mature gland, the target tissue involved in the acquisition of genetic alterations over the span of a human lifetime. To this end, we generated a murine line, ARR2PB-CreER(T2), expressing a 4-hydroxy-tamoxifen (OHT)-inducible Cre recombinase, Cre-ER(T2), under the control of the ARR2-rat probasin composite promoter [21]. This novel system allows temporal control over the timing of gene deletions in the prostatic epithelium.
###end p 6
###begin p 7
###xml 201 205 201 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 268 272 268 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 686 690 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 754 758 754 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 145 149 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 724 729 <span type="species:ncbi:10090">mouse</span>
Since the prostate epithelium undergoes rapid growth at puberty, we hypothesized that this might account for the rapid progression of disease in mice expressing constitutive Cre-triggered deletions of Pten. Supporting this idea, we found that OHT-induced Cre-mediated Pten excisions in the gland after puberty led to the very gradual development of a range of premalignant lesions. Over the course of a year these mice went on to develop high-grade PIN lesions as well as invasive carcinoma. The delayed latencies occurred despite evidence of prominent activation of the pro-tumorigenic Akt/mTOR/S6K pathway at all stages of the disease. In support of the hypothesis that the timing of Pten loss is an important variable in mouse prostate tumorigenesis, Pten excisions triggered in the pre-pubertal prostate accelerated the progression to PIN and microinvasive carcinoma.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
###xml 59 64 59 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 39 64 39 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Prostate histopathology in OHT-treated ARR2PBCreER(T2)xPtenfl/fl mice
###end title 9
###begin p 10
###xml 3 7 3 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 136 140 136 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 214 219 214 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 194 219 194 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 227 232 227 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 223 232 223 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 431 436 431 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 411 436 411 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 584 593 584 593 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 594 595 594 595 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</bold>
###xml 602 605 602 605 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iii</bold>
###xml 584 606 584 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g001"><bold>Figure 1A</bold>(<bold>i</bold>) and (<bold>iii</bold>)</xref>
###xml 682 691 682 691 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 692 694 692 694 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ii</bold>
###xml 682 695 682 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g001"><bold>Figure 1A</bold>(<bold>ii</bold>)</xref>
###xml 752 761 752 761 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 762 765 762 765 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iii</bold>
###xml 752 766 752 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g001"><bold>Figure 1A</bold>(<bold>iii</bold>)</xref>
###xml 994 1003 994 1003 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 1004 1006 1004 1006 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iv</bold>
###xml 994 1007 994 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g001"><bold>Figure 1A</bold>(<bold>iv</bold>)</xref>
###xml 1177 1186 1177 1186 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 1187 1192 1187 1192 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ii&#8211;iv</bold>
###xml 1177 1193 1177 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g001"><bold>Figure 1B</bold>(<bold>ii&#8211;iv</bold>)</xref>
###xml 1198 1205 1198 1205 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 1198 1205 1198 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003940-t001"><bold>Table 1</bold></xref>
###xml 1266 1275 1266 1275 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 1276 1277 1276 1277 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</bold>
###xml 1266 1278 1266 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g001"><bold>Figure 1B</bold>(<bold>i</bold>)</xref>
###xml 1388 1395 1388 1395 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 1388 1395 1388 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003940-t001"><bold>Table 1</bold></xref>
###xml 1704 1709 1704 1709 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 1684 1709 1684 1709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 1723 1728 1723 1728 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 1719 1728 1719 1728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 1737 1752 1737 1752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)</italic>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
###xml 401 409 <span type="species:ncbi:92876|species:ncbi:32304|species:ncbi:44043">i. group</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 665 669 <span type="species:ncbi:10090">mice</span>
###xml 746 750 <span type="species:ncbi:10090">mice</span>
###xml 1140 1144 <span type="species:ncbi:10090">mice</span>
###xml 1303 1307 <span type="species:ncbi:10090">mice</span>
###xml 1753 1757 <span type="species:ncbi:10090">mice</span>
As Pten gene deletions in the prostate have been shown to lead to rapid onset of tumorigenesis, we investigated the effects of delaying Pten excisions until after the gland had developed. Thus, ARR2PBCreER(T2)xPtenfl/fl or Ptenfl/fl control mice were injected with OHT daily for 5 consecutive days starting at 6 wks of age and then sacrificed at either 4-10,16-20, or 30-40 wks p.i. In the 4-10 wks p.i. group, ARR2PBCreER(T2)xPtenfl/fl mice treated with OHT demonstrated nuclear atypia and increased prominence of nucleoli in sporadic cells within the prostatic epithelium (arrows - Figure 1A(i) and (iii)), as well as early hyperplastic lesions at 4-wks post-OHT mice (rectangle- Figure 1A(ii)) with these being more obvious at 10-wks post-OHT mice (Figure 1A(iii)). At 16-20 wks p.i. the premalignant phenotype became much more evident, such that experimental animals displayed increased cellular size and nuclear atypia, as well as abnormal cellular morphology of luminal epithelial cells (Figure 1A(iv)). Of the 13 experimental animals, 11 contained focal areas with hyperplastic lesions ranging from mild to pronounced, and 6 out the mice exhibited advanced PIN lesions (Figure 1B(ii-iv) and Table 1). Control animals did not display these phenotypic changes (Figure 1B(i)) except perhaps for two mice with mild focal thickening of the luminal epithelium likely due to hyperplasia (Table 1). There was no additional progression past PIN lesions in 4 experimental animals when these were aged to 30-40 wks p.i., however, the PIN lesions became more prominent, and showed a wider area of distribution within the prostate (data not shown). Furthermore, none of the non-OHT exposed ARR2PBCreER(T2)xPtenfl/fl, control Ptenfl/fl, or the ARR2PBCreER(T2) mice developed any evidence of premalignant lesions in their prostates (data not shown).
###end p 10
###begin title 11
###xml 100 105 100 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 80 105 80 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
Transition from the earliest stages of transformation to occur progressively in ARR2PBCreER(T2)xPtenfl/fl mice following OHT exposure.
###end title 11
###begin p 12
###xml 1039 1044 1039 1044 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 1035 1044 1035 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 1178 1183 1178 1183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 1158 1183 1158 1183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 997 1001 <span type="species:ncbi:10090">mice</span>
###xml 1184 1188 <span type="species:ncbi:10090">mice</span>
(A) Nuclear enlargement with prominent and multiple nucleoli is seen in the luminal epithelial layer at different times post-OHT; in single cells at 4 wks post-OHT (arrows (i)); becoming more widespread at 8-10 wks post-OHT (arrows (iii)) and in the majority of cells in PIN lesions at 16-20 wks post-OHT (iv). Low grade hyperplasia is seen in the luminal layer at 4 wks post-OHT (rectangle (ii)). At 10 wks post-OHT, hyperplasia became more pronounced and nuclear enlargement with prominent nucleoli and hyperchromasia became more prevalent (arrows (iii)). Early stages of PIN, such as nuclear overlapping and mild tufting are noticeable by 10 wks post-OHT (iii). At 16-20 wks post-OHT more advanced PIN stages were evident (iv), with overt tubular dysplasia while basement membranes remained unbreached. PIN was prominent and most cells within these lesions showed nuclear enlargement, prominent nucleoli, hyperchromasia, and abnormal morphology (iv). (B) High grade PIN lesions were present in mice at 16-20 wks post-OHT. (i) While Ptenfl/fl controls showed normal morphology after OHT treatment, PIN lesions are seen 16-20 wks post-OHT administration in ARR2PBCreER(T2)xPtenfl/fl mice, with different categories of high grade PIN being evident; including as tufting, micropapillary and flat atypia (ii), and cribriform structures (iii) and (iv) were seen in both focal intra-tubular as well as the more widespread lesions in the experimental animals. Scale bars: 50 microm.
###end p 12
###begin title 13
###xml 44 59 44 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)</italic>
###xml 64 69 64 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 60 69 60 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Morphologic alterations in the prostates of ARR2PBCreER(T2)xPtenfl/fl mice injected at 6 wks of age, and subjected to histopathological analysis 16-20 wks post-OHT exposure.
###end title 13
###begin p 14
Abnormal cellular morphology refers to nuclear enlargement, prominent nucleoli, hyperchromasia, and deviations in cell size and appearance.
###end p 14
###begin p 15
Atypical nuclear morphology refers to nuclei displaying nuclear and nucleolar enlargement and increased number of nucleoli.
###end p 15
###begin title 16
###xml 77 82 77 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 57 82 57 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Increased proliferation in the epithelium of OHT-treated ARR2PBCreER(T2)xPtenfl/fl mice
###end title 16
###begin p 17
###xml 123 128 123 128 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 103 128 103 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 266 275 266 275 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2B</bold>
###xml 266 275 266 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g002"><bold>Figure 2B</bold></xref>
###xml 425 434 425 434 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2D</bold>
###xml 425 434 425 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g002"><bold>Figure 2D</bold></xref>
###xml 462 467 462 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 458 467 458 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 539 554 539 554 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2A and C</bold>
###xml 539 554 539 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g002"><bold>Figure 2A and C</bold></xref>
###xml 755 764 755 764 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2E</bold>
###xml 755 764 755 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g002"><bold>Figure 2E</bold></xref>
###xml 764 765 764 765 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">)</bold>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
The Ki67 marker was used to show the level of proliferation in the prostatic epithelium of OHT-treated ARR2PBCreER(T2)xPtenfl/fl mice. At 4-10 wks post-OHT treatment, Cre-positive animals demonstrated increased numbers of luminal epithelial cells positive for Ki67 (Figure 2B). This effect was much more pronounced at 16-20 wks post-OHT and as would be predicted, was especially striking in the hyperplastic and PIN lesions (Figure 2D). In contrast, control Ptenfl/fl prostates treated with OHT contained few, if any, Ki67-positive cells (Figure 2A and C). These findings demonstrated that loss of Pten was accompanied by a progressive increase in epithelial cell proliferation as shown by quantification of Ki67-positive cells at 4-10 wks and 16-20 wks (Figure 2E).
###end p 17
###begin title 18
###xml 86 91 86 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 66 91 66 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
There is increased cell proliferation in the luminal epithelia of ARR2PBCreER(T2)xPtenfl/fl mice exposed to OHT.
###end title 18
###begin p 19
###xml 132 137 132 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 112 137 112 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 284 289 284 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 280 289 280 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 345 350 345 350 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 325 350 325 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 433 438 433 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 413 438 413 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 582 587 578 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 562 587 558 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
###xml 439 444 <span type="species:ncbi:10090">mouse</span>
Immunohistochemical analyses revealed increased numbers of proliferating cells within the luminal epithelium of ARR2PBCreER(T2)xPtenfl/fl mice treated with OHT at 6 wks of age as indicated by Ki67 staining, as shown by the dark dots and arrows in (B) and (D). (A) and (C) control Ptenfl/fl at 10 wks and 20 wks post-OHT; (B) ARR2PBCreER(T2)xPtenfl/fl at 10 wks post-OHT and a (D) a representative PIN lesion in a ARR2PBCreER(T2)xPtenfl/fl mouse at 20 wks post-OHT. Scale bar: 50 microm. (E) Quantification of the percentage of proliferating cells in control and ARR2PBCreER(T2)xPtenfl/fl aged for 4-10 wks and 16-20 wks post-OHT injections. There is a significant increase in the percentage of proliferating cells in the PIN regions of 16-20 p.i. experimental animals both over control animals and the normal regions within the experimental animals (p-value<0.001).
###end p 19
###begin title 20
###xml 35 40 35 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 15 40 15 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
PIN lesions of ARR2PBCreER(T2)xPtenfl/fl OHT-exposed mice demonstrate Pten deficiency
###end title 20
###begin p 21
###xml 77 82 77 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 73 82 73 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 92 101 92 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 102 103 102 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</bold>
###xml 92 104 92 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003"><bold>Figure 3A</bold>(<bold>i</bold>)</xref>
###xml 181 186 181 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 161 186 161 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 215 224 215 224 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 225 227 225 227 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ii</bold>
###xml 215 228 215 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003"><bold>Figure 3A</bold>(<bold>ii</bold>)</xref>
###xml 309 318 309 318 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 319 323 319 323 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i&#8211;ii</bold>
###xml 309 324 309 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003"><bold>Figure 3B</bold>(<bold>i&#8211;ii</bold>)</xref>
###xml 418 427 418 427 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 428 431 428 431 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iii</bold>
###xml 418 432 418 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003"><bold>Figure 3B</bold>(<bold>iii</bold>)</xref>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 655 659 <span type="species:ncbi:10090">mice</span>
When compared to the levels of Pten in the luminal epithelium of control Ptenfl/fl animals (Figure 3A(i)), Pten protein deficiency was evident in PIN lesions of ARR2PBCreER(T2)xPtenfl/fl mice at 16-20 wks OHT p.i. (Figure 3A(ii)). At 4-10 wks p.i., Pten deficiency was seen in a small number of cells (arrows Figure 3B(i-ii)), and loss of Pten immunoreactivity was particularly evident in hyperplastic regions (arrows Figure 3B(iii)). These results were consistent with Pten deficiency being present in a subset of cells that together with increased proliferation and additional genetic events gradually evolved into the PIN lesions observed in the older mice. As only a few cells in a given tubule tended to show loss of Pten immunoreactivity at 4-10 wks post-OHT exposure, it suggested that Pten excisions at the epithelial stem cell level may have been infrequent.
###end p 21
###begin title 22
###xml 84 97 84 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreERT2</italic>
###xml 102 107 102 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 98 107 98 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 108 112 <span type="species:ncbi:10090">mice</span>
Downstream components of the PI3K signaling pathway are activated in PIN lesions of ARR2PBCreERT2xPtenfl/fl mice post-OHT exposure.
###end title 22
###begin p 23
###xml 177 182 177 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 173 182 173 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 635 640 635 640 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 615 640 615 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 1196 1201 1196 1201 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 1192 1201 1192 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 183 187 <span type="species:ncbi:10090">mice</span>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
###xml 1210 1215 <span type="species:ncbi:10090">mouse</span>
(A) Immunohistochemistry showing decreased Pten levels in a representative PIN lesion ((ii) bottom panel); top panel (i) shows Pten levels in prostate epithelium of control Ptenfl/fl mice. Immunohistochemistry revealed increased levels of phospho-AKT, phospho-mTOR, phospho-4E-BP1, eIF4E, and phospho-S6 (bottom panels (iv); (vi); (viii); (x); (xii) respectively) in PIN regions of positive animals (bottom panels) as compared to controls (top panels (iii); (v); (vii); (ix); (xi)). (B) Pten loss in the prostatic epithelium is associated with increase in pS6 ribosomal protein levels in the preneoplastic phase of ARR2PBCreER(T2)xPtenfl/fl mice post-OHT. Serial sections stained with either anti-Pten or anti-pS6 antibodies showed that loss of Pten could be correlated with increased phospho-S6 signal and that this could be detected at the single cell level during early time points post-OHT (arrows), even at a time when cellular and nuclear atypia were not present; as indicated by the red arrows - (ii) and (vi) 4 wks; (iii) and (vii) 8 wks; (iv) and (viii) 10 wks post-OHT. (i) and (v) show Pten, and phospho-S6 immunoreactivity, respectively, in serial sections form the prostate of a Ptenfl/fl control mouse 8 wks post-OHT. Scale bars: A (i-xii), 100 microm; B (i-vi), 37.5 microm.
###end p 23
###begin title 24
###xml 75 80 75 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 55 80 55 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Evidence for PI3K pathway activation in PIN lesions of ARR2PBCreER(T2)xPtenfl/fl mice 16-20 wks post-OHT treatment
###end title 24
###begin p 25
###xml 341 346 341 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 321 346 321 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 353 362 353 362 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 363 365 363 365 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iv</bold>
###xml 366 368 366 368 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vi</bold>
###xml 353 369 353 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003"><bold>Figure 3A</bold>(<bold>iv</bold>,<bold>vi</bold>)</xref>
###xml 501 510 501 510 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 511 515 511 515 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">viii</bold>
###xml 516 517 516 517 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">x</bold>
###xml 518 521 518 521 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">xii</bold>
###xml 501 522 501 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003"><bold>Figure 3A</bold>(<bold>viii</bold>,<bold>x</bold>,<bold>xii</bold>)</xref>
###xml 698 707 698 707 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 708 710 708 710 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ii</bold>
###xml 698 711 698 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003"><bold>Figure 3A</bold>(<bold>ii</bold>)</xref>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 799 803 <span type="species:ncbi:10090">mice</span>
###xml 842 846 <span type="species:ncbi:10090">mice</span>
To assess PI3K pathway activity components known to be affected by the loss of Pten were examined by immunohistochemistry of paraffin sections from mice 16-20 wks post-OHT exposure, these included: AKT, mTOR, 4E-BP1, eIF4E and S6. Levels of phospho-AKT and phospho-mTOR were upregulated in the PIN lesions of OHT-treated ARR2PBCreER(T2)xPtenfl/fl mice (Figure 3A(iv,vi)). The levels of phospho-4E-BP1, eIF4E, and phospho-S6-ribosomal protein immunoreactivity were also upregulated in the PIN lesions (Figure 3A(viii,x,xii)), indicating that the AKT/mTOR/S6K axis was activated in the prostatic lesions. This feature, obvious in PIN lesions as these contained large numbers of Pten deficient cells (Figure 3A(ii)), was also observed in hyperplastic regions of 16-20 wks post-OHT treated experimental mice and even in isolated tubular cells in mice at 4-10 wks post-OHT treatment (data not shown).
###end p 25
###begin title 26
Direct correspondence between Pten deficiency and phospho-S6 ribosomal protein upregulation in pre-neoplastic epithelial cell lesions
###end title 26
###begin p 27
###xml 103 108 103 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 83 108 83 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 239 248 239 248 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 249 251 249 251 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ii</bold>
###xml 239 252 239 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003"><bold>Figure 3A</bold>(<bold>ii</bold>)</xref>
###xml 254 263 254 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 264 269 264 269 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i&#8211;iii</bold>
###xml 254 270 254 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003"><bold>Figure 3B</bold>(<bold>i&#8211;iii</bold>)</xref>
###xml 572 581 572 581 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 582 591 582 591 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i,ii,iv,v</bold>
###xml 572 592 572 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003"><bold>Figure 3B</bold>(<bold>i,ii,iv,v</bold>)</xref>
###xml 692 701 692 701 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3B</bold>
###xml 702 708 702 708 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iii,vi</bold>
###xml 692 709 692 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003"><bold>Figure 3B</bold>(<bold>iii,vi</bold>)</xref>
Pten-deficient cell numbers were higher in the juxta-luminal epithelial regions of ARR2PBCreER(T2)xPtenfl/fl prostates post-OHT treatment and these were associated with cellular and nuclear atypia, as well as hyperplastic regions and PIN (Figure 3A(ii); Figure 3B(i-iii)). By performing immunohistochemistry for Pten and phospho-S6 ribosomal protein on sequential sections, we found that cells and regions lacking Pten also expressed high levels of phospho-S6, even at 4-10 wks p.i. This phenomenon was even evident within single cells at the earliest time points (arrows Figure 3B(i,ii,iv,v)), becoming more dramatic within Pten-deficient cells contained within hyperplastic regions (arrows Figure 3B(iii,vi)). These results demonstrated that there was a direct correlation between Pten-deficiency and increased S6 kinase activity, and that this feature was present early on, well before the appearance of histologically evident cellular and nuclear atypia, or hyperplasia.
###end p 27
###begin title 28
###xml 48 53 48 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 28 53 28 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Progression to carcinoma in ARR2PBCreER(T2)xPtenfl/fl mice 42-52 wks post-OHT
###end title 28
###begin p 29
###xml 229 237 229 237 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 237 247 237 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(i and ii)</bold>
###xml 229 247 229 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g004"><bold>Figure 4</bold><bold>(i and ii)</bold></xref>
###xml 353 361 353 361 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 363 366 363 366 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iii</bold>
###xml 353 367 353 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g004"><bold>Figure 4</bold> (<bold>iii</bold>)</xref>
###xml 418 426 418 426 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 428 430 428 430 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iv</bold>
###xml 418 431 418 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g004"><bold>Figure 4</bold> (<bold>iv</bold>)</xref>
###xml 704 712 704 712 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 714 715 714 715 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</bold>
###xml 704 716 704 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g004"><bold>Figure 4</bold> (<bold>v</bold>)</xref>
###xml 887 895 887 895 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 897 899 897 899 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vi</bold>
###xml 887 900 887 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g004"><bold>Figure 4</bold> (<bold>vi</bold>)</xref>
Progression from PIN to invasive carcinomas was seen in experimental animals at 42-52 wks post-OHT administration. We found that the area composed of PIN lesions increased greatly with aging, with multiple glands developing PIN (Figure 4(i and ii)). There were proliferating cells within these lesions as shown by immunostaining with the Ki67 antibody (Figure 4 (iii) arrows) and high levels of phospho-S6 expression (Figure 4 (iv)), indicating that pAKT/pmTOR/pS6 pathway had remained active. Immunohistochemistry for cytokeratins 1, 5, 10 and 14 (clone 34B12 from Dako), that stains basal cells, showed that while normal glands within the same animal maintained basal cell cytokeratin staining (arrows Figure 4 (v)), the PIN lesions in the animals aged for 42-52 wks aged animals had progressed to carcinoma as suggested by the lack of cytokeratin staining for basal cells (red arrows Figure 4 (vi)).
###end p 29
###begin title 30
###xml 73 78 73 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 53 78 53 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
Transition from PIN to invasive carcinoma is seen in ARR2PBCreER(T2)xPtenfl/fl mice exposed to OHT and aged for 42-52 wks.
###end title 30
###begin p 31
(i) Widespread high grade PIN lesions were seen in multiple glands within the prostates of experimental animals at 42-52 wks post-OHT, (ii) with abnormal cellular and nuclear morphology and microinvasive lesions (arrows). (iii) Proliferating cells within these lesions were detected by immunostaining with the anti-Ki67 antibody (arrows; arrowhead shows a mitotic figure) and high levels of phospho-S6 expression were also detected (iv). Representative immunohistochemical analysis using an antibody against high molecular cytokeratins 1,5,10, and 14 that stains basal cells: although basal cytokeratin staining was present within normal-appearing glands (v) (black arrows), with progression to invasive carcinoma there was a lack of cytokeratin staining (vi) (red arrows) within the same prostate. Scale bars: (i), 100 microm; (ii-vi), 25 microm.
###end p 31
###begin title 32
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 129 134 129 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 109 134 109 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 135 139 <span type="species:ncbi:10090">mice</span>
Accelerated progression to PIN and microinvasive carcinoma when Pten is deleted in the prostates of 2 wk-old ARR2PBCreER(T2)xPtenfl/fl mice
###end title 32
###begin p 33
###xml 147 155 147 155 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 147 155 147 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g005"><bold>Figure 5</bold></xref>
###xml 160 167 160 167 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 160 167 160 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003940-t002"><bold>Table 2</bold></xref>
###xml 252 260 252 260 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 261 262 261 262 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</bold>
###xml 252 263 252 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g005"><bold>Figure 5</bold>(<bold>i</bold>)</xref>
###xml 292 300 292 300 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 302 304 302 304 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ii</bold>
###xml 292 305 292 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g005"><bold>Figure 5</bold> (<bold>ii</bold>)</xref>
###xml 626 634 626 634 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 634 642 634 642 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(iii&#8211;iv)</bold>
###xml 626 642 626 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g005"><bold>Figure 5</bold><bold>(iii&#8211;iv)</bold></xref>
###xml 751 759 751 759 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 760 763 760 763 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iii</bold>
###xml 751 764 751 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g005"><bold>Figure 5</bold>(<bold>iii</bold>)</xref>
###xml 883 891 883 891 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 893 895 893 895 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vi</bold>
###xml 883 896 883 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g005"><bold>Figure 5</bold> (<bold>vi</bold>)</xref>
###xml 1065 1073 1065 1073 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 1075 1076 1075 1076 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">v</bold>
###xml 1065 1077 1065 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g005"><bold>Figure 5</bold> (<bold>v</bold>)</xref>
###xml 1176 1184 1176 1184 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5</bold>
###xml 1186 1188 1186 1188 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vi</bold>
###xml 1176 1189 1176 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g005"><bold>Figure 5</bold> (<bold>vi</bold>)</xref>
###xml 53 57 <span type="species:ncbi:10090">mice</span>
A wide range of lesions was seen in the prostates of mice that had been injected with OHT at 2 wks of age and then aged for 4-6 wks and 10-12 wks (Figure 5 and Table 2). Nuclear atypia and abnormal cellular morphology, as well as hyperplastic regions (Figure 5(i)) and low grade PIN lesions (Figure 5 (ii)) were already evident in animals aged for 4-6 wks p.i. Importantly, at 10-12 wks p.i. the phenotype became much more pronounced such that all of the experimental animals displayed increased cell size and nuclear atypia, abnormal cellular morphology of luminal epithelial cells, hyperplastic lesions, and high grade PIN (Figure 5(iii-iv)). Two of the 6 experimental animals in this age group had even developed microinvasive carcinoma (arrows in Figure 5(iii)). Stromal thickening, suggestive of an invasive phenotype, was noticeable in animals at 10-12 weeks p.i. (blue arrows Figure 5 (vi)). At both 4-6 wks and 10-12 wks p.i., Cre-positive animals were found to have increased numbers of luminal epithelial cells positive for the proliferation marker Ki67 (Figure 5 (v) shows a representative experimental animal at 4-6 wks p.i) and were also positive for phospho-S6 (Figure 5 (vi) shows a representative experimental animal at 4-6 wks p.i).
###end p 33
###begin title 34
###xml 45 50 45 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 25 50 25 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Histological analysis of ARR2PBCreER(T2)xPtenfl/fl mice exposed to OHT at 2 wks of age.
###end title 34
###begin p 35
###xml 20 25 20 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 0 25 0 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 417 422 <span type="species:ncbi:10090">mouse</span>
ARR2PBCreER(T2)xPtenfl/fl injected at 2 wks of age displayed a wide range of lesions by 10-12 wks post-OHT: (i) hyperplastic lesion, (ii) PIN, (iii) high grade PIN with occasional microinvasive cells (arrows), (iv) high grade PIN lesions with a wide distribution area, stromal invasion of epithelial cells (yellow arrowheads) and displaying stromal thickening (blue arrows), (v) increased proliferation in a positive mouse aged for 6 wks as indicated by Ki67 staining, (vi) positive phospho-S6 staining of a positive animal at 6 wks post-OHT). Scale bars: (i-iii and v-vi), 50 microm; (iv), 100 microm.
###end p 35
###begin title 36
###xml 44 59 44 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)</italic>
###xml 64 69 64 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 60 69 60 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
Morphologic alterations in the prostates of ARR2PBCreER(T2)xPtenfl/fl mice injected at 2 wks of age, and subjected to histopathological analysis 10-12 wks post-OHT exposure.
###end title 36
###begin p 37
Abnormal cellular morphology refers to nuclear enlargement, prominent nucleoli, hyperchromasia, and deviations in cell size and appearance.
###end p 37
###begin p 38
Atypical nuclear morphology refers to nuclei displaying nuclear and nucleolar enlargement and increased number of nucleoli.
###end p 38
###begin title 39
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
Increased apoptosis observed in prostatic epithelium following Pten gene deletion
###end title 39
###begin p 40
###xml 109 114 109 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 89 114 89 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 194 200 194 200 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 6</bold>
###xml 202 203 202 203 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 194 204 194 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g006"><bold>Fig. 6</bold> (<bold>B</bold>)</xref>
###xml 268 274 268 274 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 6</bold>
###xml 276 277 276 277 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 268 278 268 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g006"><bold>Fig. 6</bold> (<bold>D</bold>)</xref>
###xml 479 488 479 488 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6E</bold>
###xml 479 488 479 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g006"><bold>Figure 6E</bold></xref>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
TUNEL assay was used to show the level of apoptotic cells in the prostatic epithelium of ARR2PBCreER(T2)xPtenfl/fl mice previously treated with OHT either at 2 wks and then aged for 6 wks p.i. (Fig. 6 (B)), or treated with OHT at 6 wks and then aged for 4-10 wks p.i (Fig. 6 (D)). In both groups, Cre-positive animals revealed increased numbers of apoptotic luminal epithelial cells as compared to controls (p-value<0.001) as shown by the quantification of TUNEL-positive cells (Figure 6E). These results showed that loss of Pten was accompanied by a significant increase in epithelial cell death.
###end p 40
###begin title 41
###xml 78 83 78 83 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 58 83 58 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
There is increased cell death in the luminal epithelia of ARR2PBCreER(T2)xPtenfl/fl mice exposed to OHT.
###end title 41
###begin p 42
###xml 101 106 101 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 81 106 81 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 200 205 200 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 180 205 180 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 346 351 346 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 326 351 326 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 465 470 465 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 445 470 445 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 206 210 <span type="species:ncbi:10090">mice</span>
###xml 352 356 <span type="species:ncbi:10090">mice</span>
There were increased numbers of apoptotic cells within the luminal epithelium of ARR2PBCreER(T2)xPtenfl/fl mice treated with OHT at 2 wks of age and aged for 6 wks (B) and also in ARR2PBCreER(T2)xPtenfl/fl mice treated with OHT and aged for 4-10 wks (D). (E) Quantification of the percentage of apoptotic cells in control and ARR2PBCreER(T2)xPtenfl/fl mice. There was a significant increase in the percentage of apoptotic cells over controls in ARR2PBCreER(T2)xPtenfl/fl injected with OHT either at 2 wks and 6 wks of age (p-value<0.001). Scale bar: 50 microm.
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Wu1">[17]</xref>
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Greenberg2">[22]</xref>
###xml 168 172 168 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Zhang1">[24]</xref>
###xml 186 190 186 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Kasper2">[18]</xref>
###xml 472 476 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Kasper2">[18]</xref>
###xml 835 839 835 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Wu1">[17]</xref>
###xml 841 845 841 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Maddison1">[25]</xref>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Kasper2">[18]</xref>
###xml 297 302 <span type="species:ncbi:9606">human</span>
Prostate-specific promoters such as the composite probasin promoter used herein have previously been employed to generate a wide variety of transgenic lines [17], [22]-[24]; reviewed in [18]. These have enabled evaluation of the consequences of prostate-specific expression of genes implicated in human prostate cancer. Germline knockout models, where all cells in the animal harbor the genetic alteration, have also been used to study prostate tumorigenesis (reviewed in [18]). However, owing to the lack of cell-type specific deletion in the latter, it has been difficult to attribute the resulting phenotypes solely to a defect within the prostatic epithelium. Thus, in the last few years, conditional gene alterations have been used to investigate the ability of specific mutations to promote the development of prostate neoplasia [17], [25] (reviewed in [18]).
###end p 44
###begin p 45
###xml 377 380 377 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Wang1">[4]</xref>
###xml 382 386 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Kasper1">[14]</xref>
###xml 387 391 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Wu1">[17]</xref>
###xml 421 430 421 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flox/flox</sup>
###xml 410 430 410 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PBCre4&#215;Pten<sup>flox/flox</sup></italic>
###xml 453 457 453 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Wu1">[17]</xref>
###xml 472 476 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Kasper2">[18]</xref>
###xml 759 763 759 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Kasper2">[18]</xref>
###xml 502 507 <span type="species:ncbi:9606">human</span>
###xml 661 667 <span type="species:ncbi:10090">murine</span>
###xml 737 742 <span type="species:ncbi:9606">human</span>
###xml 873 879 <span type="species:ncbi:9606">humans</span>
###xml 978 984 <span type="species:ncbi:9606">humans</span>
Various models of prostate cancer have shown that mutations in tumor suppressors, or activation of oncogenes during androgen-induced gland development at puberty can lead to prostate cancer. In such models, however, tumor progression often occurs at an accelerated pace with progression to adenocarcinomas and invasive carcinomas being evident within a few weeks after puberty [4], [14]-[17]. For example, the PBCre4xPtenflox/flox prostate cancer model [17]; (reviewed in [18]) has been shown to mimic human prostate cancer development, including progression from hyperplasia to PIN, to adenocarcinoma and metastasis. As such, this appears to be one of the few murine models that replicates the spectrum of grades and stages observed in human prostate cancer [18]. However, the age at which invasive tumors are observed in this model would correspond to early adulthood in humans and do not accurately reflect the more protracted developmental time-course of prostate cancer in humans.
###end p 45
###begin p 46
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Luchman1">[21]</xref>
###xml 603 607 603 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 663 668 663 668 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 643 668 643 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 827 831 827 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Ratnacaram1">[26]</xref>
###xml 1019 1024 1019 1024 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 1015 1024 1015 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 1129 1133 1129 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Ratnacaram1">[26]</xref>
###xml 1268 1272 1268 1272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1494 1498 1494 1498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 246 251 <span type="species:ncbi:10090">mouse</span>
###xml 573 579 <span type="species:ncbi:9606">humans</span>
Conditional mutagenesis systems permitting external control over the timing of genetic alterations are attractive as they allow phenotypic analyses of mutations in the context of the mature, or even aged, prostate gland. The inducible transgenic mouse model we previously developed [21] has allowed us to induce prostate luminal epithelial cell-specific gene excisions in a temporally controlled manner. This is a valuable feature given that genetic and epigenetic alterations accumulated by the mature gland likely play a role in driving progression of prostate cancer in humans. Indeed, we found that Pten excisions in prostates of 6 wk-old ARR2PBCreER(T2)xPtenfl/fl resulted in a very gradual progression to PIN and invasive carcinoma. Our findings are in agreement with the recently published results of Ratnacaram et al., [26] who showed that the CreER(T2) expressed under the control of the PSA (prostate specific antigen) promoter yielded a similarly slowed pace of disease progression when crossed onto the Ptenfl/fl background. In our experiments, where we used 10-fold less OHT (0.1 mg per day) than Ratnacaram et al., [26] (1 mg per day), to activate CreER(T2) over a one-week period, we obtained a very similar pattern of disease progression stemming from Pten deletion in the adult animals. These two sets of results, using two different prostate-specific promoter transgene systems to drive CreER(T2) recombinase expression, support the idea that the developmental stage at which Pten is excised can affect the pace of prostate tumorigenesis.
###end p 46
###begin p 47
###xml 19 23 19 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 128 136 128 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g001">Figure 1</xref>
###xml 329 338 329 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003">Figure 3B</xref>
###xml 453 462 453 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g003">Figure 3B</xref>
###xml 807 816 807 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g001">Figure 1B</xref>
###xml 961 969 961 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g004">Figure 4</xref>
###xml 801 805 <span type="species:ncbi:10090">mice</span>
###xml 899 903 <span type="species:ncbi:10090">mice</span>
###xml 1307 1312 <span type="species:ncbi:9606">human</span>
We have shown that Pten deletions, in the mature prostate leads to a wide range of pre-malignant lesions, and as illustrated by Figure 1, even very early lesions could be resolved. We also obtained immunohistochemical evidence of cell signaling aberrations, consistent with the loss of Pten, and these were discernable early on (Figure 3B) within isolated populations of epithelial cells. For example, Pten loss was accompanied by increased pS6 levels (Figure 3B(iv-vi)) even prior to any morphological signs of atypia. Thus, although loss of the Pten tumor suppressor and increased PI3K pathway signaling is a key initiating factor in tumorigenesis, it appears that additional cytogenetic or epigenetic events must occur prior to the development of the PIN lesions as observed at later stages in our mice (Figure 1B). Interestingly, we did not observe progression past high grade PIN lesions until mice had been aged for almost a year post-OHT administration (Figure 4). The nature of the acquired genetic events required to promote tumor progression in our model remain to be elucidated. The application of new genomics and proteomics techniques to our model, with its gradual stepwise development of pathological lesions, could be useful in identifying sequences of alterations of potential relevance to human prostate cancer, and in particular, cancers featuring the loss of PTEN.
###end p 47
###begin p 48
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 273 281 273 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g005">Figure 5</xref>
###xml 373 381 373 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g005">Figure 5</xref>
###xml 482 486 482 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 609 618 609 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flox/flox</sup>
###xml 598 618 598 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PBCre4&#215;Pten<sup>flox/flox</sup></italic>
###xml 827 830 827 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Wang1">[4]</xref>
###xml 831 838 831 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003940-t003">Table 3</xref>
###xml 856 865 856 865 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flox/flox</sup>
###xml 845 865 845 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PBCre4&#215;Pten<sup>flox/flox</sup></italic>
###xml 960 965 960 965 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 940 965 940 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 1089 1093 1089 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1178 1187 1178 1187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flox/flox</sup>
###xml 1167 1187 1167 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PBCre4&#215;Pten<sup>flox/flox</sup></italic>
###xml 1209 1213 1209 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1291 1298 1291 1298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003940-t003">Table 3</xref>
###xml 1333 1337 1333 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1387 1390 1387 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Backman1">[5]</xref>
###xml 1413 1418 1413 1418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 1401 1418 1401 1418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMTVCre&#215;Pten<sup>fl/fl</sup></italic>
###xml 1452 1456 1452 1456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 79 83 <span type="species:ncbi:10090">mice</span>
###xml 736 740 <span type="species:ncbi:10090">mice</span>
###xml 866 870 <span type="species:ncbi:10090">mice</span>
###xml 966 970 <span type="species:ncbi:10090">mice</span>
###xml 1188 1192 <span type="species:ncbi:10090">mice</span>
###xml 1419 1424 <span type="species:ncbi:10090">mouse</span>
In contrast to the results obtained when Pten deletion was triggered by OHT in mice at 6 wks of age, Pten excisions induced immediately prior to the onset of puberty led to more rapid pace of disease progression, with PIN lesions already being present at 4-6 wks post-OHT (Figure 5), and high grade PIN lesions and microinvasive carcinoma developing at 10-12 wks post-OHT (Figure 5). This result was striking given that progression past PIN was only seen at 42-52 wks post-OHT when Pten excisions were triggered at 6 wks of age. For the purposes of comparison, we also established the constitutive PBCre4xPtenflox/flox model that progresses rapidly from PIN to adenocarcinoma and metastases. In our colony, disease progression in these mice was modestly delayed (by a few weeks) as compared to what was reported by Wang et al, [4](Table 3), the PBCre4xPtenflox/flox mice developed invasive carcinomas and adenocarcinomas at a time when the ARR2PBCreER(T2)xPtenfl/fl mice treated with OHT at 2 wks of age, were starting to develop microinvasive carcinomas. Thus, in our model, excisions of Pten induced at 2 wks of age more closely resembled the phenotype observed in PBCre4xPtenflox/flox mice, while delaying Pten excision until after puberty greatly slowed the pace of disease development (Table 3). The importance of the timing of Pten deletions was also highlighted by Backman et al. [5] using the MMTVCrexPtenfl/fl mouse model. In this case, early Pten deletions led to epithelial hyperplasia as early as 5 days of age and high-grade PIN and prostate carcinoma by 2 wks of age.
###end p 48
###begin title 49
###xml 51 56 51 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 40 56 40 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PbCre4&#215;Pten<sup>fl/fl</sup></italic>
###xml 82 87 82 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 61 87 61 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2 )&#215;Pten<sup>fl/fl</sup></italic>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
Timelines of disease progression in the PbCre4xPtenfl/fl and ARR2PBCreER(T2 )xPtenfl/fl mice injected with OHT either at two weeks or six weeks.
###end title 49
###begin p 50
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 404 408 404 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Thomson1">[27]</xref>
###xml 560 567 560 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 710 714 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Memarzadeh1">[28]</xref>
###xml 734 738 734 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1028 1032 1028 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Salmena1">[29]</xref>
###xml 705 709 <span type="species:ncbi:10090">mice</span>
What accounted for the more aggressive disease course when Pten excisions were induced prior to gland maturation? Growth factors and other signals that are able to drive the PI3K pathway may differ between the juvenile and adult glands. For example, fibroblast growth factor 10 expression is prominent in the mesenchyme surrounding the developing prostate but is then switched off once the gland matures [27]. Furthermore, and suggesting a mechanism whereby Pten deletion in the developing gland might be especially tumorigenic, it was recently shown using an in vivo epithelial-stromal reconstitution system that enhanced mesenchymal expression of FGF10 led to the formation of multifocal PIN lesions in mice [28]. Also, the loss of Pten just prior to puberty, a time when epithelial proliferation is much more prominent that in the mature gland, could mean that more cells are placed at risk of transformation as a result of the chromosomal instability that has been proposed to accompany loss of Pten expression (reviewed in [29]).
###end p 50
###begin p 51
###xml 6 10 6 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 260 264 260 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 475 479 475 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 629 633 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Salmena1">[29]</xref>
###xml 746 750 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Chen1">[30]</xref>
###xml 776 781 776 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trp53</italic>
###xml 850 854 850 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 964 969 964 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trp53</italic>
###xml 974 978 974 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1081 1085 1081 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1230 1234 1230 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1239 1244 1239 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trp53</italic>
###xml 1244 1248 1244 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Chen1">[30]</xref>
###xml 1273 1277 1273 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1422 1425 1422 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Ma1">[6]</xref>
###xml 1453 1457 1453 1457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1710 1718 1710 1718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003940-g006">Figure 6</xref>
###xml 1860 1864 1860 1864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 802 807 <span type="species:ncbi:10090">mouse</span>
###xml 1032 1036 <span type="species:ncbi:10090">mice</span>
###xml 1721 1725 <span type="species:ncbi:10090">mice</span>
While Pten excision obviously initiates the progression from hyperplasia to PIN in our mice, lack of Pten by itself, especially in the mature prostate, was not sufficient to generate the more advanced lesions typical of the constitutively active Cre models of Pten excision. While this might reflect excision frequencies within the gland, it could also be due to an intrinsic difference between the developing versus the mature gland that determines how the cells respond to Pten loss. For example, it has been suggested that of the lack of PTEN can be detrimental to tumour growth in the absence of other mutations (reviewed in [29]), and complete loss of this tumour suppressor can promote a senescence response that opposes tumour progression [30]. It was found that while Trp53 inactivation in the mouse prostate failed to produce neoplasia, and Pten inactivation produced non-lethal invasive prostate cancer after a long latency, the combined inactivation of Trp53 and Pten in the prostate elicited invasive prostate cancer in mice as young as two weeks of age. In this case, Pten inactivation was found to trigger growth arrest through a p53-dependent cellular senescence response that was 'rescued' by the combined loss of Pten and Trp53[30]. It was also shown that Pten inactivation in the prostate correlated with an increased proliferation rate of the epithelial cells, but not with a reduced level of apoptosis [6]. This suggested that while Pten inactivation promotes tumorigenesis there are also mechanisms at play which may push the Pten-deficient cells towards apoptosis. Although we found evidence of increased apoptosis within our experimental animals treated either at 2 wks or 6 wks of age (Figure 6), mice injected at 2 wks still progressed to PINs and microinvasive cancer more rapidly suggesting that the delayed latencies seen following Pten excision at 6 wks of age might have been a consequence of tumorigenic changes being targeted to a residual population of cells that had evaded the Pten loss-induced senescence response. Lastly, it is possible that the prostate progenitors responsible for the rapid pubertal growth of the gland are less susceptible to the senescence-promoting effect of Pten deficiency.
###end p 51
###begin p 52
###xml 21 30 21 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flox/flox</sup>
###xml 10 30 10 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PBCre4&#215;Pten<sup>flox/flox</sup></italic>
###xml 51 54 51 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Wang1">[4]</xref>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 436 440 436 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 915 918 915 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Wang1">[4]</xref>
###xml 933 937 933 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1279 1283 1279 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1416 1420 1416 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1563 1572 1563 1572 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flox/flox</sup>
###xml 1552 1572 1552 1572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PBCre4&#215;Pten<sup>flox/flox</sup></italic>
###xml 1649 1653 1649 1653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1767 1771 1767 1771 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 1573 1577 <span type="species:ncbi:10090">mice</span>
Using the PBCre4xPtenflox/flox model, Wang et al., [4] showed that, Pten loss can lead to increased stem/progenitor cell proliferation, which in turn may be associated with prostate tumor initiation and progression. However, the authors did not rule out the possibility that Pten loss might also be able to promote the transformation of cells with limited replicative capacity, providing them with self-renewal potential. In our model, Pten deletion in the mature glad did not result in early invasive adenocarcinomas and metastases, suggesting that loss of Pten within a differentiating population with low proliferative potential might only have a limited ability to augment residual proliferative capacity. In the adult prostate the number of self-renewing cells would be smaller than in the developing prostate, and this could be a factor in the slower pace of tumor progression seen in our model. Wang et al., [4] proposed that Pten loss may either increase the pool of stem and early progenitor cells, or that it might be a transforming event in non-actively dividing cells, leading them to acquire self-renewing proliferative potential. Since we did not observe rapid progression to invasive carcinoma and have not as yet seen metastases, it is possible that in our model Pten deletions are confined to cells with more limited self-renewal capacity. This observation was reinforced by the results of inducing Pten excisions in the developing prostate. While the progression through the various disease stages is not as rapid as that seen in the PBCre4xPtenflox/flox mice, we did see an accelerated phenotype as compared to that observed when Pten was excised in the fully developed prostate. In summary, our results suggest that the tumor promoting effects of Pten deficiency are highly dependent on the developmental stage of the prostate.
###end p 52
###begin title 53
Materials and Methods
###end title 53
###begin title 54
Genotyping
###end title 54
###begin p 55
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PB-CreER(T2)</italic>
###xml 22 26 22 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Luchman1">[21]</xref>
###xml 191 207 191 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flox/flox(fl/fl)</sup>
###xml 187 207 187 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>flox/flox(fl/fl)</sup></italic>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 208 212 <span type="species:ncbi:10090">mice</span>
ARR2PB-CreER(T2) mice [21] were genotyped using the following primers to verify for germline transmission: HPRT-FP: cct tac ctt tca gaa gta ggc and CreER(T2)2: atc aac gtt ttc ttt tcg g. Ptenflox/flox(fl/fl) mice were genotyped with Pten Flox-1: ctc ctc tac tcc att ctt ccc and Pten Flox-2: act ccc acc aat gaa caa ac.
###end p 55
###begin title 56
In vivo experiments
###end title 56
###begin p 57
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Singh1">[31]</xref>
###xml 237 241 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003940-Singh1">[31]</xref>
###xml 263 268 263 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 243 268 243 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 675 680 675 680 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 655 680 655 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)&#215;Pten<sup>fl/fl</sup></italic>
###xml 686 691 686 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 682 691 682 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 696 711 696 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ARR2PBCreER(T2)</italic>
###xml 794 798 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 269 273 <span type="species:ncbi:10090">mice</span>
###xml 286 290 <span type="species:ncbi:10090">mice</span>
###xml 355 359 <span type="species:ncbi:381124">corn</span>
###xml 491 495 <span type="species:ncbi:10090">mice</span>
###xml 574 578 <span type="species:ncbi:10090">mice</span>
###xml 712 716 <span type="species:ncbi:10090">mice</span>
###xml 810 814 <span type="species:ncbi:10090">Mice</span>
Animals (mixed 129;C57BL/6 background) were injected with OHT at 6 wks of age, a time when stereological evaluation reveals the prostate to be fully developed [31] and at 2 wks of age, a time when prostate development is just commencing [31]. ARR2PBCreER(T2)xPtenfl/fl mice and control mice lacking the Cre transgene were injected i.p. with 0.1 mg OHT in corn oil vehicle for five consecutive days and then allowed to age for the following periods: 4-10, 16-20, 30-40, and 42-52 wks for the mice injected at 6 wks of age; and for 4-6 and 10-12 wks post-injection (p.i.) for mice injected with OHT at 2 wks of age. Furthermore, a cohort of non-OHT-exposed ARR2PBCreER(T2)xPtenfl/fl, Ptenfl/fl and ARR2PBCreER(T2) mice were left to age for 16-20 wks to control for the possibility of spontaneous Pten excisions. Mice were housed in a viral antibody-free barrier facility in accordance with Canadian Council on Animal Care, and the University of Calgary Animal Care committee guidelines.
###end p 57
###begin title 58
Histology and Immunohistochemistry
###end title 58
###begin p 59
###xml 204 206 200 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th</sup>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 434 439 <span type="species:ncbi:10090">mouse</span>
###xml 468 473 <span type="species:ncbi:10090">mouse</span>
###xml 500 506 <span type="species:ncbi:9986">rabbit</span>
###xml 532 538 <span type="species:ncbi:9986">rabbit</span>
###xml 566 572 <span type="species:ncbi:9986">rabbit</span>
###xml 601 607 <span type="species:ncbi:9986">rabbit</span>
###xml 816 821 <span type="species:ncbi:10090">mouse</span>
###xml 837 843 <span type="species:ncbi:9986">rabbit</span>
The dissected lower urogenital tracts of the mice were fixed in 10% formaldehyde, embedded in paraffin and sectioned at 5 microm. Sections were de-paraffinized with xylene and graded alcohols and every 10th section was stained with hematoxylin and eosin (H&E) for microscopy. For immunohistochemistry, sections were de-paraffinized as above and antigen retrieval was performed using 10 mM sodium citrate, pH 6.0. Antibodies used were mouse anti-Pten antibody (1:120); mouse anti-phospho-AKT (1:200); rabbit anti-phospho-mTOR (1:7); rabbit anti-phospho-4E-BP1 (1:5); rabbit anti-eIF4E antibody (1:10); rabbit anti-phospho-S6 ribosomal protein (Ser 240/244) antibody (1:100) (all from Cell Signaling). Anti-high molecular weight cytokeratin antibody clone 34BE12 (1:100) was from Dako; and either the Vectastain Elite mouse IgG kit or the rabbit IgG ABC kit from Vector Laboratories were used as the secondary reagents. Color development was performed with DAB substrate (Sigma-Aldrich) and sections were counterstained with hematoxylin.
###end p 59
###begin title 60
Apoptosis assay
###end title 60
###begin p 61
###xml 267 274 263 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 45 49 <span type="species:ncbi:10090">mice</span>
The dissected lower urogenital tracts of the mice were fixed in 10% formaldehyde, embedded in paraffin, and sectioned at 5 microm. Sections were de-paraffinized with xylene and graded alcohols prior to the TUNEL assay, which was performed with the ApopTag peroxidase in situ apoptosis detection kit according to the manufacturer's instruction (Chemicon International, Inc., Temecula, CA).
###end p 61
###begin title 62
Quantification of proliferation and apoptosis
###end title 62
###begin p 63
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
The proliferation index was determined as the percentage of Ki67-positive cells over total cells counted. At least 500 cells per animal were counted over 5 different fields of view and 3-4 mice were included per group. Quantification of apoptosis was performed in a similar manner by determining the percentage of TUNEL positive cells over total number of cells, except that 1000 cells were counted per animal (n = 3-4 mice per group). Student T-Test (two-tailed; unequal variance) was used for statistical analyses.
###end p 63
###begin p 64
###xml 209 214 209 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">fl/fl</sup>
###xml 205 214 205 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten<sup>fl/fl</sup></italic>
###xml 169 175 <span type="species:ncbi:8164">Suzuki</span>
###xml 215 219 <span type="species:ncbi:10090">mice</span>
We are very grateful to Drs. P. Chambon and D. Metzger for providing us with the CreER(T2) cDNA; to Dr. P.J. Rennie for the ARR2PB promoter; and to Drs. T.W. Mak and A. Suzuki for generously providing the Ptenfl/fl mice. We also thank C. Horton; V. deFreitas and K.Whitney for the excellent animal care and help with the genotyping.
###end p 64
###begin title 65
References
###end title 65
###begin article-title 66
Integrative biology of prostate cancer progression.
###end article-title 66
###begin article-title 67
Molecular pathology of prostate cancer.
###end article-title 67
###begin article-title 68
Integrative Biology of prostate cancer progression.
###end article-title 68
###begin article-title 69
###xml 34 40 <span type="species:ncbi:10090">murine</span>
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.
###end article-title 69
###begin article-title 70
###xml 53 57 <span type="species:ncbi:10090">mice</span>
Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten.
###end article-title 70
###begin article-title 71
###xml 47 52 <span type="species:ncbi:10090">mouse</span>
Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
###end article-title 71
###begin article-title 72
Pten dose dictates cancer progression in the prostate.
###end article-title 72
###begin article-title 73
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.
###end article-title 73
###begin article-title 74
Signalling through Class I PI3Ks in mammalian cells.
###end article-title 74
###begin article-title 75
The PI3K-PDK1 connection: more than just a road to PKB.
###end article-title 75
###begin article-title 76
PTEN function in normal and neoplastic growth.
###end article-title 76
###begin article-title 77
Current development of mTOR inhibitors as anticancer agents.
###end article-title 77
###begin article-title 78
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse modeling in oncologic preclinical and translational research.
###end article-title 78
###begin article-title 79
Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene.
###end article-title 79
###begin article-title 80
###xml 32 37 <span type="species:ncbi:10090">mouse</span>
Prostate cancer in a transgenic mouse.
###end article-title 80
###begin article-title 81
###xml 103 118 <span type="species:ncbi:10090">transgenic mice</span>
Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice.
###end article-title 81
###begin article-title 82
###xml 65 70 <span type="species:ncbi:10090">mouse</span>
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation.
###end article-title 82
###begin article-title 83
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.
###end article-title 83
###begin article-title 84
Cancer statistics, 2007.
###end article-title 84
###begin article-title 85
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse models of prostate carcinogenesis.
###end article-title 85
###begin article-title 86
Temporally controlled prostate epithelium-specific gene alterations.
###end article-title 86
###begin article-title 87
###xml 4 7 <span type="species:ncbi:10116">rat</span>
###xml 146 161 <span type="species:ncbi:10090">transgenic mice</span>
The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice.
###end article-title 87
###begin article-title 88
Selective activation of the probasin androgen-responsive region by steroid hormones.
###end article-title 88
###begin article-title 89
A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo.
###end article-title 89
###begin article-title 90
###xml 51 66 <span type="species:ncbi:10090">transgenic mice</span>
Prostate specific expression of Cre recombinase in transgenic mice.
###end article-title 90
###begin article-title 91
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
Temporally controlled ablation of PTEN in adult mouse prostate epithelium generates a model of invasive prostatic adenocarcinoma.
###end article-title 91
###begin article-title 92
Prostatic growth and development are regulated by FGF10.
###end article-title 92
###begin article-title 93
Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor.
###end article-title 93
###begin article-title 94
Tenets of PTEN tumor suppression.
###end article-title 94
###begin article-title 95
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
###end article-title 95
###begin article-title 96
###xml 28 33 <span type="species:ncbi:10090">mouse</span>
Stereological evaluation of mouse prostate development.
###end article-title 96
###begin p 97
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 97
###begin p 98
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported in its initial stages by a National Cancer Institute of Canada/Prostate Cancer Research Initiative Pilot Grant and subsequently the Alberta Cancer Board (to F.R.J). A.C.P was supported by Genome Quebec and Genome Canada; H.A.L held fellowships from both the Alberta Heritage Foundation for Medical Research and the Alberta Cancer Board. F.R.J. was the recipient of a Canada Research Chair. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 98

